AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains

Zacks11-12

AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company lost 12.6% on Monday in response to the disappointing news. However, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483111038?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/D3ML88PGy1H5kHT9yl7OAw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326","is_english":true,"pubTime":"2024-11-12 22:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483111038","market":"us","top_or_hot":-1,"title":"AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains","media":"Zacks","content":"<div>\n<p>AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company lost 12.6% on Monday in response to the disappointing news. However, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/abbvie-stock-declines-schizophrenia-studies-143000633.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-12 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/abbvie-stock-declines-schizophrenia-studies-143000633.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company lost 12.6% on Monday in response to the disappointing news. However, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/abbvie-stock-declines-schizophrenia-studies-143000633.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1074936037.SGD","symbol_name":"JPMorgan Funds - US Value A (acc) SGD","start_time":0,"source_url":"https://finance.yahoo.com/news/abbvie-stock-declines-schizophrenia-studies-143000633.html","article_id":"2483111038","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/D3ML88PGy1H5kHT9yl7OAw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483111038","pubTimestamp":1731421800,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"The studies were designed to show a statistically significant reduction  in the change from baseline in the Positive and Negative Syndrome Scale  total score upon treatment with the candidate compared with the placebo group at week 6. Please note that PANSS isa metric that measures the symptom severity of schizophrenia.The two phase II EMPOWERstudies evaluated emraclidineas a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms. Emraclidineis a potential novel M4-selective PAMin development for schizophrenia and Alzheimer's disease psychosis as a once-daily medication without the need for titration. Year to date, shares of AbbVie have gained 12.6% compared with the industry’s 11.5% growth.ABBV’s Schizophrenia Study Failures Boost BMY Stock. The failure of the EMPOWERstudies is a huge benefit for Bristol Myers as it reduces emerging competition for Cobenfy, which could have resulted in the stock price rise ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BIIB":"渤健公司","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","ABBV":"艾伯维公司","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","BK4581":"高盛持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","ALLO":"Allogene Therapeutics Inc.","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BMY":"施贵宝","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","BK4550":"红杉资本持仓"},"translate_title":"精神分裂症研究失败，艾伯维股价下跌，BMY上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLO":1,"BIIB":1,"ABBV":1,"BMY":1},"content_text":"AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company lost 12.6% on Monday in response to the disappointing news. However, Bristol Myers’ BMY stock was up 10.5% following ABBV’s news.\nThe studies were designed to show a statistically significant reduction (improvement) in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score upon treatment with the candidate compared with the placebo group at week 6. Please note that PANSS is a metric that measures the symptom severity of schizophrenia.\nThe two phase II EMPOWER studies evaluated emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms. Emraclidine is a potential novel M4-selective PAM in development for schizophrenia and Alzheimer's disease psychosis as a once-daily medication without the need for titration. Year to date, shares of AbbVie have gained 12.6% compared with the industry’s 11.5% growth.\nImage Source: Zacks Investment Research\nABBV reported that the candidate was overall well-tolerated in the EMPOWER studies, demonstrating a safety profile consistent with that observed in a previous early-stage study. Adverse events related to treatment with emraclidine were mostly mild-to-moderate in severity. Currently, AbbVie plans to analyze these results further to determine the next steps in the development process of the candidate for the schizophrenia indication.\nWe remind the investors that emraclidine was added to AbbVie’s neuroscience pipeline through the acquisition of Cerevel. The transaction also added several other clinical-stage and preclinical candidates being developed for neurological indications like psychiatry, migraine and Parkinson's disease.\n\nAbbVie Inc. Price and Consensus\n\nAbbVie Inc. price-consensus-chart | AbbVie Inc. Quote\n\nABBV’s Schizophrenia Study Failures Boost BMY Stock\nAbbVie was developing emraclidine to rival Bristol Myers’ Cobenfy (xanomeline and trospium chloride), also an oral medication for the treatment of schizophrenia in adults, which was approved by the FDA in September 2024. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which have long been the standard of care.\nHowever, BMY’s Cobenfy has a different mechanism of action than ABBV’s emraclidine. Cobenfy is aimed at treating schizophrenia by selectively targeting M 1 and M 4 receptors in the brain without blocking D 2 receptors. Year to date, shares of Bristol Myers have gained 16.4% against the industry’s 1.2% decline.\nImage Source: Zacks Investment Research\nThe failure of the EMPOWER studies is a huge benefit for Bristol Myers as it reduces emerging competition for Cobenfy, which could have resulted in the stock price rise on Monday. Bristol Myers had acquired Cobenfy from the acquisition of Karuna Therapeutics.\n\nBristol Myers Squibb Company Price and Consensus\n\nBristol Myers Squibb Company price-consensus-chart | Bristol Myers Squibb Company Quote\n\nABBV and BMY’s Zacks Rank\nAbbVie currently carries a Zacks Rank #2 (Buy), while Bristol Myers has a Zacks Rank #3 (Hold).\nOther Stocks to Consider\nSome other top-ranked pharma stocks are Allogene Therapeutics ALLO and Biogen BIIB, each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nAllogene Therapeutics’ loss estimates have remained constant at $1.41 per share for 2024 over the past 60 days, while that for 2025 has narrowed from $1.46 to $1.45 per share. ALLO’s shares have lost 3.7% year to date.\nAllogene Therapeutics’ earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 9.42%.\nBiogen’s earnings estimates have risen from $16.12 to $16.38 per share for 2024 over the past 60 days, while that for 2025 has increased from $17.09 to $17.16. BIIB’s shares have lost 33.5% year to date.\nBiogen’s earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 9.99%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBiogen Inc. (BIIB) : Free Stock Analysis Report\nBristol Myers Squibb Company (BMY) : Free Stock Analysis Report\nAbbVie Inc. (ABBV) : Free Stock Analysis Report\nAllogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483111038"}